PrintBUSINESS STRATEGY
Surviving in a Changing Environment
Podcast: May 3, 2010The Burrill Report (May 3, 2010): Biotech's Recurring Lesson-Take the Money When You Can (.MP3,11.5 Mb)
As the biotechnology industry gathers in Chicago this week for its largest annual convention, it finds itself in a vastly improved state from a year ago. Once again, to the surprise of many, biotech companies have proved to be more resilient than thought. Through a combination of cost-cutting, creative financing, and a willingness to accept deals on less favorable terms, many companies have managed to live to fight another day. We spoke to Glen Giovannetti, global biotechnology leader for Ernst & Young, about the company’s latest report on the industry, the growing divide between biotech’s haves and have nots, and what companies will need to do to raise money and be successful in the current environment.
[Please login to post comments]
- Let's Make a Deal
Podcast May 10, 2010 Read More - Sanofi Complains About Canada's Bias for Generics As It Cuts Jobs
Company takes issue with lack of sufficient intellectual property protection. Read More - InterMune's Terrible, Horrible, No Good, Very Bad Day
FDA says it wants another trial before it will approve experimental drug for fatal lung disease. Read More - Wondering About A Potential Wonder Drug
GSK suspends trial of Sirtris’ experimental therapy. Read More - Ariad’s New Deal
Revised agreement with Merck refills biotech’s coffers. Read More - J&J; Unit Announces Voluntary Recall of Over-the Counter Kid's Drugs
The weekly round-up of failed trials, missed targets and other business mishaps. Read More - A Bright Spot in the Economy
Bioscience jobs show some growth despite recession. Read More - A Caregiver’s Toll
The stress of taking care of a partner with dementia boosts likelihood of a spouse developing the same condition. Read More - A New Super Detective
New technology identifies bacteria, viruses, other organisms within 24 hours. Read More - Medtech Brings in Life Sciences Venture Dollars
The weekly wrap-up of financings and deals. Read More
.gif)
- Exclusive: Obscure biotech Regeneron on verge of big league
Reuters - FDA to look into gene tests to be sold at Walgreen
Reuters - Walgreen Stores to Sell Spit-and-Mail Gene Testing Kits in U.S.
Bloomberg - Merck to Seek U.S. Approval for 5 New Drugs in 2010
Bloomberg - New Obama Strategy Treats ‘War’ on Drugs as Public Health Issue
Bloomberg - Memo to boss: 11-hour days are bad for the heart
Reuters - Florida Suit Poses a Challenge to Health Care Law
The New York Times - Glaxo Said to Pay $60 Million in Avandia Settlements
Bloomberg - Keeping Junior on Parent’s Insurance Is a Tax Benefit
Bloomberg - Payment Offers to Egg Donors Prompt Scrutiny
The New York Times